ReviewSeminars in liver disease2010
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.
Review in Seminars in liver disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 166 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigation of Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
Biomarker Discovery Through Multiomics Study in Advanced Hepatocellular Carcinoma Patients Who Received Atezolizumab and Bevacizumab Combination Therapy
Who cites it
166 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Expression of genes that control core fucosylation in hepatocellular carcinoma: Systematic review.World journal of gastroenterology · 2019Pooled it
- Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.Gut and liver · 2013Trial
- Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Trial
- Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.The oncologist · 2012Trial
- Navigating the Labyrinth of Hepatocellular Carcinoma: Leveraging AI/ML for Precision Oncology.Oncology research · 2026Review
- Deep learning facilitated discovery of prognosis biomarkers and their ligands to improve liver cancer treatment.International journal of surgery (London, England) · 2026Article
- Decision-Making Biomarkers Guiding Therapeutic Strategies in Hepatocellular Carcinoma: From Prediction to Personalized Care.Cancers · 2025Review
- MicroRNA-1303 in cancer pathogenesis and therapy: clinical implications for biomarker development and targeted treatment strategies.Cancer cell international · 2025Review
- Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway.Clinical and molecular hepatology · 2025Article
- Identification of Hepatocellular Carcinoma Subtypes Based on Global Gene Expression Profiling to Predict the Prognosis and Potential Therapeutic Drugs.Biomedicines · 2025Article
- Pseudouridylation-Related Genes Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma Patients.Journal of Cancer · 2025Article
- Immune-related cell death index and its application for hepatocellular carcinoma.NPJ precision oncology · 2024Article
- Review
- γδ T Cells: A Game Changer in the Future of Hepatocellular Carcinoma Immunotherapy.International journal of molecular sciences · 2024Review
- Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.International journal of molecular sciences · 2024Article
- Deciphering the Prognostic and Therapeutic Value of a Gene Model Associated with Two Aggressive Hepatocellular Carcinoma Phenotypes Using Machine Learning.Journal of hepatocellular carcinoma · 2024Article
- Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma.Hepatology forum · 2024Review
- Imaging prognostication and tumor biology in hepatocellular carcinoma.Journal of liver cancer · 2023Article
- Hepatocellular Carcinoma: Past and Present Challenges and Progress in Molecular Classification and Precision Oncology.International journal of molecular sciences · 2023Review
- Validation for models for tumor recurrence after liver transplantation in hepatectomy patients.Annals of surgical treatment and research · 2022Article
106 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is one of most lethal cancers worldwide. Strategic decisions for the advancement of molecular therapies in this neoplasm require a clear understanding of its molecular classification. Studies indicate aberrant activation of signaling pathways involved in cellular proliferation (e.g., epidermal growth factor and RAS/mitogen-activated protein kinase pathways), survival (e.g., Akt/mechanistic target of rapamycin pathway), differentiation (e.g., Wnt and Hedgehog pathways), and angiogenesis (e.g., vascular endothelial growth factor and platelet-derived growth factor), which is heterogeneously presented in each tumor. Integrative analysis of accumulated genomic datasets has revealed a global scheme of molecular classification of HCC tumors observed across diverse etiologic factors and geographic locations. Such a framework will allow systematic understanding of the frequently co-occurring molecular aberrations to design treatment strategy for each specific subclass of tumors. Accompanied by a growing number of clinical trials of molecular targeted drugs, diagnostic and prognostic biomarker development will be facilitated with special attention on study design and with new assay technologies specialized for archived fixed tissues. A new class of genomic information, microRNA dysregulation and epigenetic alterations, will provide insight for more precise understanding of disease mechanism and expand the opportunity of biomarker/therapeutic target discovery. These efforts will eventually enable personalized management of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.